Tailored management of advanced thyroid cancer patients treated with lenvatinib or vandetanib: the role of a multimodal approach.

Kinase inhibitor Loco-regional treatment Personalized therapy Tumour board

Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
02 Oct 2024
Historique:
received: 30 07 2024
accepted: 24 09 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: aheadofprint

Résumé

In differentiated/poorly differentiated (DTC/PDTC) or medullary thyroid cancer (MTC) treated with kinase inhibitors (KIs), additional treatments (ATs) can be performed in selected cases. We retrospectively analysed all the ATs performed in our center in KI-treated TC patients, evaluating the subsequent KI modulation, the local PD in case of loco-regional procedure (LRP) and the AT-related complications. DTC/PDTC patients with or without progressive disease before the first AT (PD and NO PD GROUP, respectively) were analysed separately. In our center, 32 ATs (30 LRPs and 2 radioactive iodine treatments) were performed in 14 DTC/PDTC patients and 4 MTC subjects after the start of systemic therapy with lenvatinib or vandetanib (27 and 5 ATs, respectively). Brain was the most treated site (11/30 LRPs) and external beam radiation was the most employed LRP (18/30 LRPs). KIs dose reduction or discontinuation of KI therapy (at least transient) was performed after 50% of ATs in DTC/PDTC NO PD GROUP. The KI was maintained at the same dosage after 75% and 50% of the ATs performed in DTC/PDTC PD GROUP and MTC, respectively. During the follow-up, local PD was detected after 14 LRPs. Local progression-free survival (LPFS) was significantly shorter in DTC/PDTC PD GROUP in comparison to NO PD GROUP (12 month-LPFS 91.7% versus 15.2%); in patients with MTC, 12 month-LPFS was 50%. AT-related AEs were mostly G1-G2. In selected DTC/PDTC without previous PD and treated with a multimodal strategy, local disease control is generally maintained regardless the KI dose modulation. In DTC/PDTC patients with previous limited PD and in MTC subjects, the choice of performing a LRP and continue the ongoing KI therapy must consider the risk of early local progression. AT-related AEs in KI treated patients were mild in most cases.

Sections du résumé

BACKGROUND BACKGROUND
In differentiated/poorly differentiated (DTC/PDTC) or medullary thyroid cancer (MTC) treated with kinase inhibitors (KIs), additional treatments (ATs) can be performed in selected cases.
METHODS METHODS
We retrospectively analysed all the ATs performed in our center in KI-treated TC patients, evaluating the subsequent KI modulation, the local PD in case of loco-regional procedure (LRP) and the AT-related complications. DTC/PDTC patients with or without progressive disease before the first AT (PD and NO PD GROUP, respectively) were analysed separately.
RESULTS RESULTS
In our center, 32 ATs (30 LRPs and 2 radioactive iodine treatments) were performed in 14 DTC/PDTC patients and 4 MTC subjects after the start of systemic therapy with lenvatinib or vandetanib (27 and 5 ATs, respectively). Brain was the most treated site (11/30 LRPs) and external beam radiation was the most employed LRP (18/30 LRPs). KIs dose reduction or discontinuation of KI therapy (at least transient) was performed after 50% of ATs in DTC/PDTC NO PD GROUP. The KI was maintained at the same dosage after 75% and 50% of the ATs performed in DTC/PDTC PD GROUP and MTC, respectively. During the follow-up, local PD was detected after 14 LRPs. Local progression-free survival (LPFS) was significantly shorter in DTC/PDTC PD GROUP in comparison to NO PD GROUP (12 month-LPFS 91.7% versus 15.2%); in patients with MTC, 12 month-LPFS was 50%. AT-related AEs were mostly G1-G2.
CONCLUSIONS CONCLUSIONS
In selected DTC/PDTC without previous PD and treated with a multimodal strategy, local disease control is generally maintained regardless the KI dose modulation. In DTC/PDTC patients with previous limited PD and in MTC subjects, the choice of performing a LRP and continue the ongoing KI therapy must consider the risk of early local progression. AT-related AEs in KI treated patients were mild in most cases.

Identifiants

pubmed: 39356445
doi: 10.1007/s12020-024-04061-2
pii: 10.1007/s12020-024-04061-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet 388, 2783–2795 (2016). https://doi.org/10.1016/S0140-6736(16)30172-6
doi: 10.1016/S0140-6736(16)30172-6 pubmed: 27240885
B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016). https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020 pubmed: 26462967 pmcid: 4739132
S.A. Wells, S.L. Asa, H. Dralle et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid 25, 567–610 (2015). https://doi.org/10.1089/thy.2014.0335
doi: 10.1089/thy.2014.0335 pubmed: 25810047 pmcid: 4490627
S.A. Wells, B.G. Robinson, R.F. Gagel et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134–141 (2012). https://doi.org/10.1200/JCO.2011.35.5040
doi: 10.1200/JCO.2011.35.5040 pubmed: 22025146
M. Schlumberger, M. Tahara, L.J. Wirth et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med 372, 621–630 (2015). https://doi.org/10.1056/NEJMoa1406470
doi: 10.1056/NEJMoa1406470 pubmed: 25671254
L.D. Locati, A. Piovesan, C. Durante et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35–40 (2019). https://doi.org/10.1016/j.ejca.2019.05.031
doi: 10.1016/j.ejca.2019.05.031 pubmed: 31299580
A. Berdelou, I. Borget, Y. Godbert, T. Nguyen, M.E. Garcia, C.N. Chougnet, A. Ferru, C. Buffet, O. Chabre, O. Huillard, S. Leboulleux, M. Schlumberger, Lenvatinib for the Treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28(1), 72–78 (2018). https://doi.org/10.1089/thy.2017.0205
doi: 10.1089/thy.2017.0205 pubmed: 29048237
L. Fugazzola, R. Elisei, D. Fuhrer et al. 2019 European thyroid association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur. Thyroid J. 8, 227–245 (2019). https://doi.org/10.1159/000502229
doi: 10.1159/000502229 pubmed: 31768334 pmcid: 6873012
T. Porcelli, F. Sessa, C. Luongo, D. Salvatore, Local ablative therapy of oligoprogressive TKI-treated thyroid cancer. J. Endocrinol. Invest 42, 871–879 (2019). https://doi.org/10.1007/s40618-019-1001-x
doi: 10.1007/s40618-019-1001-x pubmed: 30628046
A. Nervo, F. Retta, A. Ragni et al. Management of progressive radioiodine-refractory thyroid carcinoma: current perspective. Cancer Manag. Res. 14, 3047–3062 (2022). https://doi.org/10.2147/CMAR.S340967
doi: 10.2147/CMAR.S340967 pubmed: 36275786 pmcid: 9584766
H.A. Yu, C.S. Sima, J. Huang et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J. Thorac. Oncol. 8, 346–351 (2013). https://doi.org/10.1097/JTO.0b013e31827e1f83
doi: 10.1097/JTO.0b013e31827e1f83 pubmed: 23407558 pmcid: 3673295
B. Qiu, Y. Liang, Q. Li et al. Local therapy for oligoprogressive disease in patients with advanced stage non–small-cell lung cancer harboring epidermal growth factor receptor mutation. Clin. Lung Cancer 18, e369–e373 (2017). https://doi.org/10.1016/j.cllc.2017.04.002
doi: 10.1016/j.cllc.2017.04.002 pubmed: 28465010
C.J. Gomes-Lima, D. Wu, S.N. Rao et al. Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes. J. Endocr. Soc. 3, 359–371 (2019). https://doi.org/10.1210/js.2018-00241
doi: 10.1210/js.2018-00241 pubmed: 30706042
A. Nervo, A. Ragni, F. Retta et al. Interventional radiology approaches for liver metastases from thyroid cancer: a case series and overview of the literature. J. Gastrointest. Cancer 52, 823–832 (2021). https://doi.org/10.1007/s12029-021-00646-6
doi: 10.1007/s12029-021-00646-6 pubmed: 33999355 pmcid: 8376701
M.E. Cabanillas, S. Takahashi, Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 46, 57–64 (2019). https://doi.org/10.1053/j.seminoncol.2018.11.004
doi: 10.1053/j.seminoncol.2018.11.004 pubmed: 30685073
D. Wu, C.J. Gomes Lima, S.L. Moreau et al. Improved survival after multimodal approach with 131I treatment in patients with bone metastases secondary to differentiated thyroid cancer. Thyroid 29, 971–978 (2019). https://doi.org/10.1089/thy.2018.0582
doi: 10.1089/thy.2018.0582 pubmed: 31017051
N.-W. Sheu, H.-J. Jiang, C.-W. Wu et al. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: case reports and literature review. World J. Surg. Oncol. 17, 84 (2019). https://doi.org/10.1186/s12957-019-1626-4
doi: 10.1186/s12957-019-1626-4 pubmed: 31103041 pmcid: 6525978
U.A. Herranz, Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer. Cancer Med. 11, 47–53 (2022). https://doi.org/10.1002/cam4.5105
doi: 10.1002/cam4.5105 pubmed: 36202606 pmcid: 9537052
E.A. Eisenhauer, P. Therasse, J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009). https://doi.org/10.1016/j.ejca.2008.10.026
doi: 10.1016/j.ejca.2008.10.026 pubmed: 19097774
(2017) Common Terminology Criteria for Adverse Events (CTCAE)
C. Colombo, S. De Leo, M. Trevisan et al. Daily management of patients on multikinase inhibitors’ treatment. Front Oncol. 12, 903532 (2022). https://doi.org/10.3389/fonc.2022.903532
doi: 10.3389/fonc.2022.903532 pubmed: 35860593 pmcid: 9290676
S. Takahashi, N. Kiyota, T. Yamazaki et al. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol. 15, 717–726 (2019). https://doi.org/10.2217/fon-2018-0557
doi: 10.2217/fon-2018-0557 pubmed: 30638399
S.A. Laurie, S. Banerji, N. Blais et al. Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. Curr. Oncol. 26, 81–93 (2019). https://doi.org/10.3747/co.26.4116
doi: 10.3747/co.26.4116
S. Filetti, C. Durante, D.M. Hartl et al. ESMO Clinical Practice Guideline update on the use of systemic therapy in advanced thyroid cancer. Ann. Oncol. 33, 674–684 (2022). https://doi.org/10.1016/j.annonc.2022.04.009
doi: 10.1016/j.annonc.2022.04.009 pubmed: 35491008
T. Alonso‐Gordoa, Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system. Cancer Med. 11, 33–39 (2022). https://doi.org/10.1002/cam4.4901
doi: 10.1002/cam4.4901 pubmed: 36202602 pmcid: 9537051
A.G. Gianoukakis, C.E. Dutcus, N. Batty et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Relat. Cancer 25, 699–704 (2018). https://doi.org/10.1530/ERC-18-0049
doi: 10.1530/ERC-18-0049 pubmed: 29752332 pmcid: 5958278
A. Farooki, V. Leung, H. Tala, R.M. Tuttle, Skeletal-related events due to bone metastases from differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 97, 2433–2439 (2012). https://doi.org/10.1210/jc.2012-1169
doi: 10.1210/jc.2012-1169 pubmed: 22564664

Auteurs

Alice Nervo (A)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy. alice.nervo@gmail.com.

Matteo Ferrari (M)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Elisa Vaccaro (E)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Enrica Migliore (E)

Cancer Epidemiology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Giovanni Gruosso (G)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Anna Roux (A)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Alessandro Piovesan (A)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Emanuela Arvat (E)

Oncological Endocrinology Unit, Department of Medical Sciences, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.

Classifications MeSH